Sungen Biomedical

What Sungen Biomedical does

Sungen Biomedical (Beijing Sungen Biomedical Technology Co., Ltd.) is a privately-held, clinical-stage biopharmaceutical company founded in 2019 and incubated by Shanghai Stock Exchange-listed Hotgen Biotech (SH.688068), which holds a majority stake. The company is headquartered in the Daxing District of Beijing and operates with 51–100 employees. Sungen focuses on the discovery and development of First-in-Class (FIC) antibody therapeutics addressing unmet clinical needs in cardiovascular disease and oncology, with two lead assets — SGC001, the world's first antibody drug for acute myocardial infarction (now in Phase II with FDA Fast Track designation), and SGT003, a CTLA4-targeting bispecific antibody for solid tumors (NMPA IND accepted April 2026).

The company's technology base comprises six proprietary platforms: NexTreg™ for bispecific antibody development, SG Linker-Payload for next-generation ADC engineering (with PCT-published patents under WO2026/086886A), a large-capacity synthetic antibody library, single B cell sorting, hybridoma, and an AI-assisted antibody discovery platform. A Pilot R&D and Production Platform supports Fed-Batch culture expression, multi-mode chromatography, and fill-finish for syringes and vials, while a Quality Control Platform handles molecular interaction, protein stability, and capillary electrophoresis analytics. SGC001 demonstrated 20.5%–38.1% infarct size reduction in Phase Ib medium and high-dose groups versus placebo, and SGT003 achieved over 30% tumor growth inhibition in preclinical models.

Sungen is pre-revenue and operates a drug development and potential future commercialization model, currently monetizing through development milestones and partnership rather than product sales. Pricing has not been publicly disclosed. Go-to-market relies on event-driven outreach via J.P. Morgan Healthcare Conference, BIO-Europe, and the China FIC Innovation & Collaboration Summit to attract global pharmaceutical partners, licensees, and investors. The company's customer-facing interactions in clinical development span over 20 participating medical centers in China, including Peking University First Hospital, Shanghai East Hospital, and Linfen Central Hospital. Founding membership in the Zhongguancun FIC Alliance (ZFIC) — covering 40+ member enterprises and 600+ innovative pipelines — and strategic incubation by Hotgen Biotech form the central ecosystem positioning.

Name

Sungen Biomedical

Legal name

Beijing Sungen Biomedical Technology Co., Ltd.

Website

https://sungenbiomed.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Sungen Biomedical is a Beijing-based, pre-revenue biopharmaceutical company developing First-in-Class antibody therapeutics for cardiovascular disease and oncology. It is majority-owned by listed Hotgen Biotech and advances SGC001 (world's first AMI antibody drug, Phase II) and SGT003 (oncology bispecific, NMPA IND accepted).

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA), Bispecific & Multispecific Antibodies (HLAAAAAF), Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)

Keywords

• Antibody therapeutics
• Bispecific antibodies
• Drug development
• Biopharmaceuticals
• Oncology research

Headquarters

HQ city

Daxing

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Drug Development and Commercialization: Sungen Biomedical generates revenue through development and potential commercialization of First-in-Class antibody drug candidates. As a pre-revenue biopharmaceutical company in clinical development stage, the company is focused on advancing multiple pipeline candidates through clinical trials toward market approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Sungen Biomedical is a clinical-stage biopharmaceutical company developing First-in-Class (FIC) antibody therapeutics for cardiovascular diseases and oncology. The company advances proprietary drug candidates SGC001 (world's first antibody drug for acute myocardial infarction) and SGT003 (bispecific antibody for tumor immunotherapy) through clinical trials, supported by internally developed technology platforms including bispecific antibody, antibody-drug conjugate (ADC), and AI-assisted antibody discovery platforms.

Product overview

Sungen Biomedical is an innovative antibody drug research and development enterprise founded in 2019, incubated by Hotgen Biotech (SH688068). The company operates as a unified portfolio of First-in-Class (FIC) antibody therapeutics organized around core technology platforms. The product portfolio centers on two lead drug candidates: SGC001 (world's first antibody drug for acute myocardial infarction, now in Phase II trials with FDA Fast Track designation) and SGT003 (bispecific antibody for tumor immunotherapy from the NexTreg™ platform, IND accepted by NMPA). These are supported by proprietary technology platforms including the SG Linker-Payload ADC platform for next-generation ADC development, the NexTreg™ bispecific antibody platform, the Molecular Discovery Platform (featuring AI-assisted antibody discovery, single B cell sorting, and synthetic antibody libraries), the Pilot R&D and Production Platform, and the Quality Control Platform. The company focuses on unmet clinical needs in cardiovascular diseases and oncology, developing original macromolecular drug pipelines with global FIC potential.

Differentiator

Problem solved

Functional benefit

Brands

• SG Linker-Payload: Proprietary ADC technology platform featuring a highly hydrophilic linker-payload structure for next-generation antibody-drug conjugate development.
• NexTreg™

Products and services

• SGC001 World's first First-in-Class monoclonal antibody drug for acute myocardial infarction (AMI). Targets the S100A8/A9 pathway to suppress inflammation and protect myocardium. Has entered Phase II clinical trials with FDA Fast Track designation.
• SGT003 Next-generation bispecific antibody for tumor immunotherapy developed on the NexTreg platform. Features dual mechanisms: precisely eliminating tumor microenvironment Tregs and activating anti-tumor immunity. Targets CTLA-4 to reduce immune-related adverse events compared to traditional CTLA-4 antibodies.
• SG Linker-Payload ADC Technology Platform Proprietary next-generation antibody-drug conjugate (ADC) technology platform featuring highly hydrophilic linker-payload structure. Addresses molecular aggregation issues in conventional ADCs, enhances drug stability, prolongs in vivo half-life, and reduces non-specific clearance risk. Enables flexible combinations between novel linkers and diverse payloads.
• NexTreg Platform Bispecific antibody technology platform for developing innovative immunotherapies. Enables precise targeting of tumor tissues, remodeling of tumor microenvironment, and triggering of body's inherent immune response against tumor cells while reducing immune-related adverse reactions. Supports dual-target drug development focusing on CTLA4.

Quantifiable outcome

• SGC001 reduced myocardial infarct size by 20.5% and 38.1% in medium and high-dose groups respectively vs placebo in Phase Ib clinical trial
• +3 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Seven partnerships are on record, tiered minor and core.

• Youngen BiotechminorOthers · 24 September 2025Youngen Biotech is a company in which Hotgen Biotech holds a minority stake. Both Youngen Biotech and Sungen Biomed (majority-owned by Hotgen) participated in the 2026 China FIC Innovation & Collaboration Summit, showcasing their respective technology platforms.
• Zhongguancun FIC Alliance (ZFIC Alliance)coreStrategic or Co-development PartnerSungen Biomedical is a founding member of the Zhongguancun FIC Alliance for Global Strategic Development of Innovative Drugs, co-sponsored by Hotgen and other leading institutions. The alliance aims to integrate upstream and downstream resources of the industrial chain, promote development and internationalization of innovative drugs with global First-in-Class potential. The alliance has over 40 member enterprises developing 600+ innovative drug pipelines including 172 FIC pipelines.
• Beijing Anzhen Hospital, Capital Medical UniversitycoreStrategic or Co-development PartnerBeijing Anzhen Hospital collaborated with Sungen Biomedical in joint development of SGC001, the world's first antibody drug for acute myocardial infarction. The hospital is part of Capital Medical University system and contributed to the clinical development of this groundbreaking therapy.
• Beijing Institute of Heart, Lung and Blood Vessel Diseases, Capital Medical UniversitycoreStrategic or Co-development PartnerProfessor Jie Du's team from Beijing Institute of Heart, Lung and Blood Vessel Diseases collaborated with Sungen's Professor Zhiwei Sun's team in development of SGC001. Professor Jie Du was selected among Top 2% Global Scientists with Lifetime Scientific Impact 2024.
• Taizhou People's HospitalminorStrategic or Co-development PartnerSungen Biomedical and Taizhou People's Hospital officially signed a contract for integration and development collaboration.
• Military Medical Research InstitutecoreStrategic or Co-development PartnerJoint application project between Military Medical Research Institute and Sungen Biomedical won the First Prize, demonstrating great scientific research capacity in collaborative research.
• National Human Brain Health Project Joint LaboratoryminorStrategic or Co-development PartnerOfficial opening ceremony of the National Human Brain Health Project Joint Laboratory was held in Beijing with Sungen Biomedical's participation.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Akeso, Inc. China-based clinical-stage biotech commercializing first-in-class bispecific antibodies (e.g., cadonilimab, ivonescimab) with oncology focus. Highly comparable to Sungen in bispecific platform strategy, FIC ambition, and target patient population, though at a significantly later commercial stage.
• Shanghai Junshi Biosciences: China-headquartered innovator developing monoclonal antibodies and bispecifics across oncology and autoimmune indications. Comparable in modality mix (mAbs and bispecifics), China-rooted R&D, and listed-company backing (HKEX: 1877), but with broader pipeline depth.
• RemeGen Co., Ltd. China-based biotech with approved ADC (disitamab vedotin) and active bispecific/mAb pipeline. Highly relevant ADC peer given Sungen's SG Linker-Payload platform focus, and a useful comparator for the China-to-global commercialization arc.
• Mabwell (Shanghai) Bioscience: Shanghai-based innovative biologics developer with pipeline spanning monoclonal antibodies, ADCs, and bispecifics. Comparable in China-rooted multi-modality antibody strategy and clinical-stage positioning.
• MacroGenics, Inc. Clinical-stage US biotech developing bispecific antibodies and ADCs against immuno-oncology targets, including multiple CTLA-4-containing programs. Highly relevant comparator for SGT003's CTLA-4 bispecific positioning and ADC platform development.

Broad incumbents

• Innovent Biologics: Large established Chinese biopharma with commercialized oncology biologics (PD-1, biosimilars) and an expanding bispecific/ADC pipeline. Comparable in therapeutic biologics focus and Chinese regulatory pathway expertise, though far more mature commercially.
• Genmab A/S: Global leader in bispecific antibody platforms (DuoBody, HexaBody) with multiple approved partnered assets. Directly comparable technology model — proprietary bispecific platforms that enable partnered pipeline expansion — and a benchmark for how a platform-centric antibody company scales.
• BeiGene, Ltd. Global oncology-focused biotech with PD-1 leadership (tislelizumab) and an expanding bispecific pipeline. Comparable in oncology mAb development and US-China dual regulatory strategy, with broader commercial scale.
• Hansoh Pharmaceutical Group: One of China's largest innovative pharma companies, with growing investment in bispecific antibodies and ADCs. Comparable in pipeline breadth across antibody modalities and the strategic shift toward FIC innovation.

Others

• WuXi Biologics: Global biologics CDMO with proprietary bispecific (WuXiBody) and antibody discovery platforms. Comparable on the discovery/CMC technology side rather than direct therapeutic competition; useful benchmark for platform scalability and global BD reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sungen Biomedical